Although NBCn1 is broadly expressed throughout the body [28], greater NBCn1-dependency at low pHo and during hypoxia and the marked (2–7-fold) upregulation of NBCn1 during breast carcinogenesis [3, 27] support that anti-tumor therapeutic effects of targeting NBCn1 can be achieved without detrimental adverse reactions from normal tissue. This evidence concerns the gene SLC4A7 and neoplasm.